688185 康希诺
交易中 07-25 14:00:48
资讯
新帖
简况
康希诺中标非免疫规划疫苗项目 券商看好助推业绩增长
自选股中标信息 · 07-24 11:04
康希诺中标非免疫规划疫苗项目 券商看好助推业绩增长
A股异动丨疫苗股集体大涨,康希诺涨超7%
金融界 · 07-24 06:07
A股异动丨疫苗股集体大涨,康希诺涨超7%
天津板块盘中拉升,绿茵生态涨9.31%
市场透视 · 07-24 05:41
天津板块盘中拉升,绿茵生态涨9.31%
港股康希诺拉升涨近14%
格隆汇 · 07-24 05:32
港股康希诺拉升涨近14%
疫苗概念股午后走高 智飞生物涨停
E公司 · 07-24 05:28
疫苗概念股午后走高 智飞生物涨停
生物制品行业盘中拉升,智飞生物涨14.73%
市场透视 · 07-24 05:14
生物制品行业盘中拉升,智飞生物涨14.73%
康希诺中标上海疫苗采购项目 券商看好买入评级
自选股中标信息 · 07-22 11:08
康希诺中标上海疫苗采购项目 券商看好买入评级
康希诺涨5.10%创近4个月新高 创新药政策利好引发短期资金博弈
智选洞察 · 07-17
康希诺涨5.10%创近4个月新高 创新药政策利好引发短期资金博弈
猴痘概念盘中拉升,康希诺涨3.11%
市场透视 · 07-17
猴痘概念盘中拉升,康希诺涨3.11%
康希诺(688185.SH):重组三价脊髓灰质炎疫苗(Sf-RVN细胞)临床试验获批准
智通财经网 · 07-16
康希诺(688185.SH):重组三价脊髓灰质炎疫苗(Sf-RVN细胞)临床试验获批准
创新FIC龙头,底部反转
瞪羚社 · 07-14
创新FIC龙头,底部反转
康希诺:基于新型ISL递送系统推进mRNA疫苗临床研究
证券之星 · 07-09
康希诺:基于新型ISL递送系统推进mRNA疫苗临床研究
生物制品行业盘中拉升,赛升药业涨7.47%
市场透视 · 07-08
生物制品行业盘中拉升,赛升药业涨7.47%
每周股票复盘:康希诺(688185)股本总额247,449,899元,未发生股份增减变动
证券之星 · 07-05
每周股票复盘:康希诺(688185)股本总额247,449,899元,未发生股份增减变动
康希诺:推进13价肺炎结合疫苗PCV13i商业化
南方财经网 · 07-04
康希诺:推进13价肺炎结合疫苗PCV13i商业化
康希诺06月26日遭主力抛售101.6万元
市场透视 · 06-26
康希诺06月26日遭主力抛售101.6万元
康希诺06月25日遭主力抛售681.5万元
市场透视 · 06-25
康希诺06月25日遭主力抛售681.5万元
康希诺:公司的重组肺炎蛋白疫苗PBPV为全球创新品种
证券之星 · 06-23
康希诺:公司的重组肺炎蛋白疫苗PBPV为全球创新品种
从PCV13i的“中国方案”进阶,来看康希诺生物(6185.HK/688185.SH)技术突围与价值重估
格隆汇 · 06-22
从PCV13i的“中国方案”进阶,来看康希诺生物(6185.HK/688185.SH)技术突围与价值重估
康希诺:13价肺炎球菌多糖结合疫苗(CRM197/破伤风类毒素)获得药品注册证书
格隆汇 · 06-20
康希诺:13价肺炎球菌多糖结合疫苗(CRM197/破伤风类毒素)获得药品注册证书
加载更多
公司概况
公司名称:
康希诺生物股份公司
所属行业:
医药制造业
上市日期:
2020-08-13
主营业务:
康希诺生物股份公司的主营业务是研发、生产和商业化符合中国及国际标准的创新型疫苗。公司的主要产品是疫苗及相关产品、药品生产工艺研究开发业务(CDMO)。公司获得了天津市制造业单项冠军企业、天津市专精特新中小企业、天津市先进级智能工厂等多个荣誉。
发行价格:
209.71
{"stockData":{"symbol":"688185","market":"SH","secType":"STK","nameCN":"康希诺","latestPrice":71.02,"timestamp":1753423248000,"preClose":71.42,"halted":0,"volume":3053605,"delay":0,"changeRate":-0.0056,"floatShares":114999999,"shares":247000000,"eps":-0.8905,"marketStatus":"交易中","change":-0.4,"latestTime":"07-25 14:00:48","open":70.97,"high":72.2,"low":69.51,"amount":217000000,"amplitude":0.0377,"askPrice":71.04,"askSize":6,"bidPrice":71.02,"bidSize":12,"shortable":0,"etf":0,"ttmEps":-0.8905,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1753426800000},"marketStatusCode":2,"adr":0,"adjPreClose":71.42,"symbolType":"stock_kcb","openAndCloseTimeList":[[1753407000000,1753414200000],[1753419600000,1753426800000]],"highLimit":78.56,"lowLimit":64.28,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":247449899,"isCdr":false,"pbRate":3.61,"roa":"--","roe":"--","epsLYR":-1.53,"committee":-0.038168,"marketValue":17574000000,"turnoverRate":0.0266,"status":1,"hkstockBrief":{"symbol":"06185","market":"HK","secType":"STK","nameCN":"康希诺生物","latestPrice":42.8,"timestamp":1753423233045,"preClose":42.85,"halted":0,"volume":1763600,"delay":0,"premium":"-45.01"},"floatMarketCap":8152000000},"requestUrl":"/m/hq/s/688185","defaultTab":"news","newsList":[{"id":"2553207682","title":"康希诺中标非免疫规划疫苗项目 券商看好助推业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2553207682","media":"自选股中标信息","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553207682?lang=zh_cn&edition=full","pubTime":"2025-07-24 19:04","pubTimestamp":1753355052,"startTime":"0","endTime":"0","summary":"2025年07月24日,据天眼查数据,重庆市奉节县疾病预防控制中心关于2025年非免疫规划疫苗遴选结果的公示显示,中标方为康希诺,招标方为重庆市奉节县疾病预防控制中心。近半年内,康希诺获得2家券商积极评价:湘财证券和国泰海通证券给予\"买入\"评级。康希诺主营业务涵盖疫苗及相关产品销售,药品生产工艺研究开发业务,其他收入之和。截至发稿,康希诺股价报71.42元,上涨7.92%,成交额至4.56亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724190413a6bf90fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724190413a6bf90fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","159646","688185"],"gpt_icon":0},{"id":"2553279385","title":"A股异动丨疫苗股集体大涨,康希诺涨超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553279385","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553279385?lang=zh_cn&edition=full","pubTime":"2025-07-24 14:07","pubTimestamp":1753337220,"startTime":"0","endTime":"0","summary":"A股市场疫苗股集体走强,其中,智飞生物20CM涨停,沃森生物涨15%,康泰生物涨超12%,康希诺、华兰疫苗涨超7%,百克生物涨6%。另外,世界卫生组织专家就蚊媒传播疾病基孔肯雅热发出警报,提醒各国做好应对准备,避免疫情大规模爆发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/24140751946144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159646","688185","399300","BK0239","159982"],"gpt_icon":0},{"id":"2553276183","title":"天津板块盘中拉升,绿茵生态涨9.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553276183","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553276183?lang=zh_cn&edition=full","pubTime":"2025-07-24 13:41","pubTimestamp":1753335701,"startTime":"0","endTime":"0","summary":"07月24日,天津板块盘中拉升,截至13点41分,天津板块整体指数上涨1.00%,报1969.890点。从个股上来看,该板块的成分股中,绿茵生态涨9.31%,康希诺、凯莱英2只股涨幅超过5%。从资金上来看,截止发稿,天津板块主力净流入为1.77亿,其中中远海控受到资金热捧,主力净流入1.25亿;拉长时间线来看,该板块近20日主力资金净流入-57.80亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724134141a4608bc8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724134141a4608bc8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688185","BK0218","06821","BK0239","002887","BK0145","BK0150"],"gpt_icon":0},{"id":"2553027521","title":"港股康希诺拉升涨近14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553027521","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553027521?lang=zh_cn&edition=full","pubTime":"2025-07-24 13:32","pubTimestamp":1753335135,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00B543WZ88.USD","IE00B5MMRT66.SGD","BK1574","688185","BK1191","BK1515","BK4614","HSCEI","LU0348784397.USD","01477","159837","LU1720050803.USD","LU1794554557.SGD","BK1161","BK0239","LU0348783233.USD","01672","07226","LU0417516571.SGD","09926","HSTECH","IE00BPRC5H50.USD","YANG","LU2488822045.USD"],"gpt_icon":0},{"id":"2553768562","title":"疫苗概念股午后走高 智飞生物涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2553768562","media":"E公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553768562?lang=zh_cn&edition=full","pubTime":"2025-07-24 13:28","pubTimestamp":1753334900,"startTime":"0","endTime":"0","summary":"人民财讯7月24日电,疫苗概念股午后走高,截至发稿,智飞生物涨停,沃森生物、康泰生物、华兰疫苗、康希诺等跟涨。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724132820a46086c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724132820a46086c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","159646","LU2580892862.HKD","688185","300122","BK0077","LU1328615791.USD","BK0239","LU2148510915.USD","BK0046","BK0196","LU1064130708.USD","LU1064131003.USD","LU2580892789.USD"],"gpt_icon":0},{"id":"2553275996","title":"生物制品行业盘中拉升,智飞生物涨14.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553275996","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553275996?lang=zh_cn&edition=full","pubTime":"2025-07-24 13:14","pubTimestamp":1753334051,"startTime":"0","endTime":"0","summary":"07月24日,生物制品行业盘中拉升,截至13点14分,生物制品行业整体指数上涨3.01%,报6791.950点。从个股上来看,该行业的成分股中,智飞生物涨14.73%,沃森生物、三生国健2只个股涨幅超过10%,康泰生物、康希诺等3只股涨幅超过5%。从资金上来看,截止发稿,生物制品行业主力净流入为6326.04万,其中智飞生物受到资金热捧,主力净流入1.79亿;拉长时间线来看,该板块近20日主力资金净流入-27.46亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724131411971b466a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724131411971b466a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0239","LU1328615791.USD","688336","BK0077","BK0196","LU2148510915.USD","300122","688185","LU1064131003.USD","LU2580892862.HKD","LU1064130708.USD","BK0046","LU2580892789.USD"],"gpt_icon":0},{"id":"2553304972","title":"康希诺中标上海疫苗采购项目 券商看好买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2553304972","media":"自选股中标信息","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553304972?lang=zh_cn&edition=full","pubTime":"2025-07-22 19:08","pubTimestamp":1753182521,"startTime":"0","endTime":"0","summary":"2025年07月22日,据天眼查数据,2025年度上海市非免疫规划疫苗集团采购拟中选产品公示显示,中标方为康希诺,招标方为上海医健卫生事务服务中心。近半年内,康希诺获得2家券商积极评价:湘财证券和国泰海通证券给予\"买入\"评级。康希诺主营业务涵盖疫苗及相关产品销售,药品生产工艺研究开发业务,其他收入之和。截至发稿,康希诺股价报66.14元,下跌1.05%,成交额至1.85亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722190851a45c3728&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722190851a45c3728&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159646","688185"],"gpt_icon":0},{"id":"2552108147","title":"康希诺涨5.10%创近4个月新高 创新药政策利好引发短期资金博弈","url":"https://stock-news.laohu8.com/highlight/detail?id=2552108147","media":"智选洞察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552108147?lang=zh_cn&edition=full","pubTime":"2025-07-17 13:08","pubTimestamp":1752728925,"startTime":"0","endTime":"0","summary":"康希诺股价今日大幅上涨,截至13点08分,最新价报66.00元/股,涨幅达5.10%,创近4个月新高。资金分歧映射政策博弈康希诺近期股价波动与资金面博弈密切相关。创新药支持政策出台触发短期投机资金介入,但二季度疫苗销售淡季叠加2025年前三季度亏损1154万元的业绩压力,促使部分资金选择兑现收益。技术转化决定价值重塑康希诺长期估值锚定技术平台商业化进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717130852a4502ff4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717130852a4502ff4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159992","688185","BK0239"],"gpt_icon":0},{"id":"2552174822","title":"猴痘概念盘中拉升,康希诺涨3.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2552174822","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552174822?lang=zh_cn&edition=full","pubTime":"2025-07-17 09:35","pubTimestamp":1752716157,"startTime":"0","endTime":"0","summary":"07月17日,猴痘概念盘中拉升,截至09点35分,猴痘概念整体指数上涨0.55%,报1056.810点。从个股上来看,该概念的成分股中,康希诺涨3.11%,透景生命、亚太药业、可孚医疗涨幅居前。从资金上来看,截止发稿,猴痘概念主力净流入为-1.27亿,其中海辰药业受到资金热捧,主力净流入480.02万;拉长时间线来看,该板块近20日主力资金净流入-34.66亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717093557a6ae841c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717093557a6ae841c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688185"],"gpt_icon":0},{"id":"2551146899","title":"康希诺(688185.SH):重组三价脊髓灰质炎疫苗(Sf-RVN细胞)临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2551146899","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551146899?lang=zh_cn&edition=full","pubTime":"2025-07-16 16:41","pubTimestamp":1752655302,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康希诺(688185.SH)公告,公司近日收到国家药品监督管理局核准签发的关于重组三价脊髓灰质炎疫苗(Sf-RVN细胞)的《药物临床试验批准通知书》,同意开展预防由脊髓灰质炎I型、II型和III型病毒感染导致的脊髓灰质炎的临床试验。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1318499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688185","BK1583","BK1576","03347","BK1141","159646","BK0239"],"gpt_icon":0},{"id":"2551318994","title":"创新FIC龙头,底部反转","url":"https://stock-news.laohu8.com/highlight/detail?id=2551318994","media":"瞪羚社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551318994?lang=zh_cn&edition=full","pubTime":"2025-07-14 20:05","pubTimestamp":1752494703,"startTime":"0","endTime":"0","summary":"上方“瞪羚社”即刻关注并加入社群聚焦高成长公司,100000+投资菁英共同关注当市场焦点都集中在创新药的底部公司挖掘时,一家创新生物制品龙头的基本面正在发生翻天覆地的变化,其不仅股价正在历史底部,并且几款核心产品都处于放量加速或上市快速放量的阶段,短期扭亏盈利路径清晰可见,这家公司便是康希诺生物。其次,“曼海欣”在临床中不良反应发生率明显较同类疫苗低,具有不错的安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714202823a449fd4b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714202823a449fd4b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","06185","688185","BK1515","BK1191"],"gpt_icon":0},{"id":"2550368547","title":"康希诺:基于新型ISL递送系统推进mRNA疫苗临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2550368547","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550368547?lang=zh_cn&edition=full","pubTime":"2025-07-09 15:36","pubTimestamp":1752046573,"startTime":"0","endTime":"0","summary":"证券之星消息,康希诺07月09日在投资者关系平台上答复投资者关心的问题。目前公司正在推进mRNA疫苗用于治疗胶质母细胞瘤等临床研究项目,该候选产品预计今年内完成首例患者给药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070900020442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688185","159646","BK0239"],"gpt_icon":0},{"id":"2549567797","title":"生物制品行业盘中拉升,赛升药业涨7.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2549567797","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549567797?lang=zh_cn&edition=full","pubTime":"2025-07-08 09:38","pubTimestamp":1751938693,"startTime":"0","endTime":"0","summary":"07月08日,生物制品行业盘中拉升,截至09点38分,生物制品行业整体指数上涨1.00%,报6293.880点。从个股上来看,该行业的成分股中,赛升药业涨7.47%,荣昌生物、康希诺、昊帆生物涨幅居前。从资金上来看,截止发稿,生物制品行业主力净流入为-2016.41万,其中荣昌生物受到资金热捧,主力净流入3863.80万;拉长时间线来看,该板块近20日主力资金净流入-39.36亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708093813979db34b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708093813979db34b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688185","300485","BK0028","BK0239","BK0012","BK0046"],"gpt_icon":0},{"id":"2549409863","title":"每周股票复盘:康希诺(688185)股本总额247,449,899元,未发生股份增减变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2549409863","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549409863?lang=zh_cn&edition=full","pubTime":"2025-07-06 06:28","pubTimestamp":1751754494,"startTime":"0","endTime":"0","summary":"截至2025年7月4日收盘,康希诺报收于60.3元,较上周的58.5元上涨3.08%。本周关注点公司公告汇总:康希诺提交证券变动月报表,法定/注册股本总额为人民币247,449,899元,未发生股份增减变动公司公告汇总康希诺H股公告显示,康希诺生物股份公司于2025年7月3日提交了证券变动月报表,报告截至2025年6月30日的数据。H股和A股的已发行股份总数分别为132,670,900股和114,778,999股,其中A股中有406,098股作为库存股持有。报告期内,公司未发生股份增减变动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070600000926.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688185","BK0239"],"gpt_icon":0},{"id":"2548358366","title":"康希诺:推进13价肺炎结合疫苗PCV13i商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2548358366","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548358366?lang=zh_cn&edition=full","pubTime":"2025-07-04 10:42","pubTimestamp":1751596925,"startTime":"0","endTime":"0","summary":"南方财经7月4日电,康希诺在2025年6月的调研中表示,公司13价肺炎结合疫苗PCV13i优佩欣具有突出的产品竞争力,该产品采用多糖抗原与蛋白载体共价结合的方式,使多糖转化为T细胞依赖性抗原,在2岁以下婴幼儿体内诱导出很高特异性抗体水平,并产生免疫记忆。公司会根据产品特性及各省招标准入情况,推进后续商业化进程。文章来源:南方财经网康希诺:推进13价肺炎结合疫苗PCV13i商业化","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704105941a4ce82b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704105941a4ce82b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688185","159646"],"gpt_icon":0},{"id":"2546678688","title":"康希诺06月26日遭主力抛售101.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546678688","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546678688?lang=zh_cn&edition=full","pubTime":"2025-06-26 15:21","pubTimestamp":1750922509,"startTime":"0","endTime":"0","summary":"06月26日, 康希诺股价跌2.10%,报收58.62元,成交金额8268.3万元,换手率1.22%,振幅2.40%,量比0.93。康希诺今日主力资金净流出101.6万元,连续3日净流出,上一交易日主力净流出681.5万元。该股近5个交易日上涨1.33%,主力资金累计净流入1167.6万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流出805.1万元,其中净流出天数为15日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626170503a4bedf29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626170503a4bedf29&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688185"],"gpt_icon":0},{"id":"2546029755","title":"康希诺06月25日遭主力抛售681.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546029755","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546029755?lang=zh_cn&edition=full","pubTime":"2025-06-25 15:19","pubTimestamp":1750835995,"startTime":"0","endTime":"0","summary":"06月25日, 康希诺股价跌0.18%,报收59.88元,成交金额6989.6万元,换手率1.02%,振幅2.55%,量比0.79。康希诺今日主力资金净流出681.5万元,上一交易日主力净流出192.3万元。该股近5个交易日上涨1.66%,主力资金累计净流入1103.0万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流出1445.2万元,其中净流出天数为15日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625165042a4bcfd55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625165042a4bcfd55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688185","BK0239"],"gpt_icon":0},{"id":"2545490473","title":"康希诺:公司的重组肺炎蛋白疫苗PBPV为全球创新品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2545490473","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545490473?lang=zh_cn&edition=full","pubTime":"2025-06-23 17:57","pubTimestamp":1750672625,"startTime":"0","endTime":"0","summary":"证券之星消息,康希诺(688185)06月23日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘,您好,最近创新药火热,各大药企的大额全球授权交易不断涌现,请问公司的PBPV有考虑过这种操作,加速应用和转化吗?康希诺回复:尊敬的投资人您好,公司的重组肺炎蛋白疫苗PBPV为全球创新品种,是一款广谱非血清型依赖肺炎疫苗,已取得I期临床试验的积极数据,正在规划后续研发活动,也在评估寻找合同方共同推进产品开发的模式。如有阶段性进展,将及时分享。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062300022322.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688185","159646"],"gpt_icon":0},{"id":"2545432607","title":"从PCV13i的“中国方案”进阶,来看康希诺生物(6185.HK/688185.SH)技术突围与价值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2545432607","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545432607?lang=zh_cn&edition=full","pubTime":"2025-06-22 20:19","pubTimestamp":1750594752,"startTime":"0","endTime":"0","summary":"从产业升级回归到产品竞争力层面,康希诺PCV13i的核心价值可沿着技术突破、临床验证、应用优化三大脉络展开。在安全性上,PCV13i的不良反应发生率与对照疫苗无统计学差异,主要不良反应均为轻度反应。PCV13i的竞争力不仅停留在技术层面,更延伸至生产应用全链条。从需求端来看,PCV13i作为肺炎疫苗的战略地位正随着临床需求的刚性化持续抬升。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/22201951229501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","BK1161","BK1574","BK0239","BK1515","688185","06185"],"gpt_icon":0},{"id":"2544149621","title":"康希诺:13价肺炎球菌多糖结合疫苗(CRM197/破伤风类毒素)获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2544149621","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544149621?lang=zh_cn&edition=full","pubTime":"2025-06-20 16:04","pubTimestamp":1750406663,"startTime":"0","endTime":"0","summary":"格隆汇6月20日丨康希诺公布,公司已获得国家药品监督管理局下发的13价肺炎球菌多糖结合疫苗《药品注册证书》,公司的PCV13i采用多糖抗原与蛋白载体共价结合的方式,多糖抗原连接载体蛋白后,多糖可以转化为T细胞依赖性抗原,不仅可以在2岁以下婴幼儿体内诱导出很高的特异性抗体水平,还可以产生记忆性B细胞,产生免疫记忆。PCV13i为公司肺炎产品组合中首个获得药品注册证书的产品,为公司更高价肺炎结合疫苗的研发奠定基础。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506201604469524715d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506201604469524715d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","159646","688185"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753423253297,"stockEarnings":[{"period":"1week","weight":0.0789},{"period":"1month","weight":0.1905},{"period":"3month","weight":0.3085},{"period":"6month","weight":0.2157},{"period":"1year","weight":0.8313},{"period":"ytd","weight":0.1699}],"compareEarnings":[{"period":"1week","weight":0.0253},{"period":"1month","weight":0.0541},{"period":"3month","weight":0.0943},{"period":"6month","weight":0.1086},{"period":"1year","weight":0.2425},{"period":"ytd","weight":0.0758}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"康希诺生物股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"17426人(较上一季度减少0.86%)","perCapita":"6586股","listingDate":"2020-08-13","address":"天津市东丽区经济技术开发区西区南大街185号西区生物医药园四层401-420","registeredCapital":"24744万元","survey":" 康希诺生物股份公司的主营业务是研发、生产和商业化符合中国及国际标准的创新型疫苗。公司的主要产品是疫苗及相关产品、药品生产工艺研究开发业务(CDMO)。公司获得了天津市制造业单项冠军企业、天津市专精特新中小企业、天津市先进级智能工厂等多个荣誉。","listedPrice":209.71},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康希诺(688185)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康希诺(688185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康希诺,688185,康希诺股票,康希诺股票老虎,康希诺股票老虎国际,康希诺行情,康希诺股票行情,康希诺股价,康希诺股市,康希诺股票价格,康希诺股票交易,康希诺股票购买,康希诺股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康希诺(688185)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康希诺(688185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}